TuHURA Biosciences, Inc. (HURA)
NASDAQ: HURA · Real-Time Price · USD
1.830
+0.070 (3.98%)
At close: Oct 15, 2026, 4:00 PM EDT
1.800
-0.030 (-1.64%)
After-hours: Oct 15, 2026, 7:30 PM EDT
TuHURA Biosciences Employees
TuHURA Biosciences had 22 employees as of December 31, 2025. The number of employees increased by 3 or 15.79% compared to the previous year. That makes TuHURA Biosciences the 38,061st largest employer in the world and 5,445th in the United States.
Employees
22
Change (1Y)
3
Growth (1Y)
15.79%
Revenue / Employee
n/a
Profits / Employee
-$1,392,365
Market Cap
116.62M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 22 | 3 | 15.79% |
| Dec 31, 2024 | 19 | 18 | 1,800.00% |
| Dec 31, 2023 | 1 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Humacyte | 184 |
| LENZ Therapeutics | 152 |
| Tonix Pharmaceuticals Holding | 142 |
| Seer, Inc. | 124 |
| Foghorn Therapeutics | 106 |
| enGene Therapeutics | 82 |
| Armata Pharmaceuticals | 61 |
| Milestone Pharmaceuticals | 38 |
HURA News
- 2 days ago - TuHURA Biosciences granted U.S. patent broadening coverage for VISTA Inhibitor - TheFly
- 2 days ago - TuHURA Biosciences Receives New U.S. Patent Broadening Coverage for its VISTA Inhibitor, TBS-2025 - PRNewsWire
- 10 days ago - TuHURA Biosciences receives U.S. patent for DOR ADC technology - TheFly
- 10 days ago - TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology - PRNewsWire
- 4 weeks ago - TuHURA Biosciences: FDA clears IND for TBS-2025 VISTA-inhibiting antibody - TheFly
- 4 weeks ago - TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood-Related Cancers - PRNewsWire
- 5 weeks ago - TuHURA Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference - PRNewsWire
- 1 month ago - TuHURA Biosciences Transcript: AGM 2026 - Transcripts